Compare CSX Corporation (CSX) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CSX Corporation vs TransMedics Group Inc — how do they compare? CSX Corporation trades at $50 (market cap $92.24B), while TransMedics Group Inc trades at $74.59 (market cap $2.58B). The key difference: CSX Corporation is far larger — about 35.8× TransMedics Group Inc's market cap, and CSX Corporation pays a 1.13% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| CSX | TMDX | |
|---|---|---|
Market Cap | $92.24B | $2.58B |
Sector | Industrials | Technology |
52-Week High | $49.92 | $150.42 |
52-Week Low | $32.05 | $61.99 |
Enterprise Value | $110.47B | $2.98B |
Dividend Yield | 1.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CSX trades at $49.64, up 0.47% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported mixed recent earnings, beating in Q1 2026 but missing in Q4 2025, with Q2 2026 results expected soon. Revenue has trended down from $14.9B in 2022 to $14.1B in 2025, though net margins remain above 20%. Strong cash flow from operations supports dividends, including a recent $0.14 payout.
Outlook is cautiously optimistic given analyst consensus favoring Buy ratings (56.52%) and a price target near $48.87. Risks include declining revenue, high debt levels, and valuation multiples above industry norms. Earnings growth and operational efficiency gains are key catalysts for upside, but macroeconomic pressures on freight demand pose headwinds.
TransMedics (TMDX) trades at $75.74, up 6.33% today, showing strong momentum despite a recent earnings miss. The stock maintains bullish technical signals with support at $75 and resistance at $77. Recent strategic investments in European organ logistics through PAD Aviation position the company for international expansion, though margin pressure from these investments remains a concern. Analyst consensus remains strongly positive with a $108.71 price target.
The outlook remains favorable with 75% analyst buy ratings and significant upside potential from current levels. Key risks include execution challenges in European expansion, ongoing margin pressure from NOP investments, and competitive threats in the transplant logistics space. Revenue growth continues at 21% year-over-year, but investors should monitor margin trends and European rollout execution closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
